Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy

Clinical and Experimental Hypertension : CHE
T TakenakaHiromichi Suzuki

Abstract

Diabetic nephropathy (DN) is a leading disease that requires renal replacement therapy. The progression of renal dysfunction in DN is faster than the other renal diseases. While antihypertensive therapy reduces albuminuria, a good indicator for the progression, hypertension in DN is treatment resistant. Among patients with DN who took angiotensin receptor blockers (ARBs), 27 patients who exhibited poor control of albuminuria were enrolled into the study. Angiotensin receptor blocker was exchanged to aliskiren (150-300 mg/d) and clinical parameters were followed for 6 months. Exchange to aliskiren decreased albuminuria (1.57 ± 0.68 to 0.89 ± 0.45 g/gCr, P < .01) without changes in estimated glomerular filtration rate and office blood pressure (BP). Body weight and hemoglobin A1c were not altered. Aliskiren also reduced plasma renin activity (2.0 ± 0.9 to 1.2 ± 0.6 ng/mL/h, P < .01). While evening BP was unchanged, morning systolic BP (139 ± 8 to 132 ± 7 mm Hg, P < .01) and diastolic BP (81 ± 7 to 76 ± 6 mm Hg, P < .05) were decreased significantly after 6 months. Our results indicated that aliskiren decreased BP, especially morning BP in hypertensive patients with DN. The present data suggest that aliskiren exerts renoprotective...Continue Reading

References

Dec 1, 1986·The Journal of Clinical Investigation·T OkudaK Kurokawa
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Jul 14, 2004·Contributions to Nephrology·Tsuneo TakenakaHideki Ikenaga
Sep 24, 2004·Atherosclerosis·Tsuneo TakenakaHiromichi Suzuki
Aug 20, 2005·American Journal of Nephrology·Tsuneo TakenakaHiromichi Suzuki
Sep 15, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tsukasa NakamuraUNKNOWN Efficacy of Candesartan on Outcome in Saitama Trial Group
Jan 17, 2007·Metabolism: Clinical and Experimental·Tsuneo TakenakaHiromichi Suzuki
May 19, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kenji TakazawaAkira Yamashina
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Yoshihiko KannoHiromichi Suzuki
Oct 6, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Keiko HosohataYutaka Imai
Oct 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·James ShepherdUNKNOWN Treating to New Targets Investigators
Dec 28, 2007·Kidney International·F C Luft, M H Weinberger
Jun 6, 2008·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN AVOID Study Investigators
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Dec 17, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Susumu OgawaSadayoshi Ito

❮ Previous
Next ❯

Citations

Mar 29, 2013·Clinical and Experimental Hypertension : CHE·Tsuneo TakenakaHiromichi Suzuki
Dec 13, 2016·Clinical and Experimental Hypertension : CHE·Tsuneo TakenakaHiromichi Suzuki
Jan 21, 2016·World Journal of Nephrology·Yoichi OhnoTsuneo Takenaka
Oct 26, 2018·Physiological Reviews·Agustin Gonzalez-VicenteJeffrey L Garvin
Feb 19, 2016·American Journal of Physiology. Renal Physiology·Vanesa D RamseyerJeffrey L Garvin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The Journal of Clinical Hypertension
Radhika Katakam, Raymond R Townsend
© 2021 Meta ULC. All rights reserved